title: Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.
abstract: Gastrinomas in dogs are difficult to diagnose, localise and treat. In humans, somatostatin analogues have improved localisation and treatment of gastrinomas. The somatostatin analogues pentetreotide and octreotide were evaluated for the detection and treatment of gastrinoma in a dog. 111indium-pentetreotide scintigraphy revealed multiple areas of activity in the patient's mid-ventral abdomen which were consistent with masses in the pancreas and liver at laparotomy. Immunohistochemistry, electron microscopy and binding of 125I-[Tyr3]-octreotide in vitro confirmed the lesion as a gastrinoma which expressed somatostatin receptors. Octreotide at doses of 2, 4 and 8 micrograms/kg caused transient decreases in circulating gastrin. Plasma somatostatin peaked at one hour after octreotide and was still detectable at four and six hours after administration of octreotide. Combination therapy with famotidine, omeprazole, sucralfate and increasing doses of octreotide allowed patient survival for 14 months.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA.
authors.forename: M
authors.initials: M
authors.lastname: Altschul
authors.forename: K W
authors.initials: KW
authors.lastname: Simpson
authors.forename: N L
authors.initials: NL
authors.lastname: Dykes
authors.forename: E A
authors.initials: EA
authors.lastname: Mauldin
authors.forename: J C
authors.initials: JC
authors.lastname: Reubi
authors.forename: J F
authors.initials: JF
authors.lastname: Cummings
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D015408:Gastrinoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary*; D005755:Gastrins / Q000097:blood; D007150:Immunohistochemistry; D007205:Indium Radioisotopes; D007279:Injections, Subcutaneous / Q000662:veterinary; D008854:Microscopy, Electron / Q000379:methods / Q000662:veterinary; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D009853:Omeprazole / Q000627:therapeutic use; D010179:Pancreas / Q000737:chemistry / Q000473:pathology / Q000648:ultrastructure; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary*; D011863:Radioimmunoassay / Q000379:methods / Q000662:veterinary; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000032:analysis; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013392:Sucralfate / Q000627:therapeutic use
chemical_list: D000897:Anti-Ulcer Agents; D018931:Antineoplastic Agents, Hormonal; D005755:Gastrins; D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D013004:Somatostatin; D013392:Sucralfate; D015738:Famotidine; C081788:pentetreotide; D009853:Omeprazole; D015282:Octreotide